1. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation
by André Tichelli, Hubert Schrezenmeier, Gérard Socié, Judith Marsh, Andrea Bacigalupo, Ulrich Dührsen, Anke Franzke, Michael Hallek, Eckhard Thiel, Martin Wilhelm, Britta Höchsmann, Alain Barrois, Kim Champion, and Jakob R. Passweg
Blood
Volume 117(17):
April 28, 2011
©2011 by American Society of Hematology

2. Six-year OS rate in patients with SAA treated with ATG/CSA with or without G-CSF.
Six-year OS rate in patients with SAA treated with ATG/CSA with or without G-CSF. (A) OS of all 192 patients; (B) OS according to disease severity, comparing patients with SAA (blue), and very SAA (green); (C) OS according to age groups: patients < 20 years (blue), patients aged years (green), patients aged years (red), and patients aged > 60 years (lilac).
André Tichelli et al. Blood 2011;117:
©2011 by American Society of Hematology

3. OS and EFS rates.
OS and EFS rates. Six-year OS rate (A) and EFS (B) in patients with SAA treated with ATG/CSA with (green) or without (blue) G-CSF.
André Tichelli et al. Blood 2011;117:
©2011 by American Society of Hematology

4. Response rates according to the time since randomization.
Response rates according to the time since randomization. (A) Patients randomly assigned to ATG/CSA without G-CSF; (B) patients randomly assigned to ATG/CSA with G-CSF.
André Tichelli et al. Blood 2011;117:
©2011 by American Society of Hematology

5. Evolution of neutrophil counts during the first year in patients treated with ATG and CSA with and without G-CSF.
Evolution of neutrophil counts during the first year in patients treated with ATG and CSA with and without G-CSF. The bold red line represents the median, and the yellow surface represents the 75% CI of the neutrophil counts in patients treated with G-CSF; the bold blue line represents the median, and the blue surface represents the 75% CI of the neutrophil counts in patients treated without G-CSF; the gray surface represents the overlapping surface of 75% CI of patients treated with and without G-CSF.
André Tichelli et al. Blood 2011;117:
©2011 by American Society of Hematology

6. Survival of patients randomly assigned to receive G-CSF with neutrophil counts ≥ 0.50 × 109/L (blue) at day 30 compared with patients with neutrophil counts < 0.50 × 109/L (green).
Survival of patients randomly assigned to receive G-CSF with neutrophil counts ≥ 0.50 × 109/L (blue) at day 30 compared with patients with neutrophil counts < 0.50 × 109/L (green).
André Tichelli et al. Blood 2011;117:
©2011 by American Society of Hematology